In addition, because B7-H3 is also expressed in tumor stromal cells and tumor stem cells, as well as the tumor neovasculature and other components of the tME, CAR-T cell therapy targeting B7-H3 may be able to destroy tumor cells and modulate the TME. Here, CD276 is linked to neoplasm.